Foghorn®-logo-color.jpg
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
March 26, 2024 07:00 ET | Foghorn Therapeutics, Inc.
Company management will review key pipeline programs, including an update on FHD-286 for AML, new preclinical data for the BRM selective inhibitor FHD-909 and for its selective CBP and EP300 degrader...
Foghorn®-logo-color.jpg
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
March 07, 2024 07:00 ET | Foghorn Therapeutics, Inc.
• Dose escalation in FHD-286 combination study in AML continues to progress; clinical data anticipated in the second half of 2024 • FHD-909, a first-in-class BRM selective inhibitor, selected for...
Foghorn®-logo-color.jpg
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, Including the Selective Inhibitor of BRM, FHD-909
March 05, 2024 16:48 ET | Foghorn Therapeutics, Inc.
Poster presentation of FHD-909, a first-in-class oral BRM selective inhibitor, highlighting preclinical efficacy and safety in multiple mouse models of NSCLC; IND filing planned in Q2 2024Oral...
Foghorn®-logo-color.jpg
Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference
February 28, 2024 07:00 ET | Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn®-logo-color.jpg
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor
February 08, 2024 07:00 ET | Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn®-logo-color.jpg
Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024
January 08, 2024 07:00 ET | Foghorn Therapeutics, Inc.
- FHD-286 combination study in AML continues to progress in the clinic with data anticipated in the second half of 2024; preclinical combination data with FHD-286 and tyrosine kinase inhibitors (TKIs)...
Foghorn®-logo-color.jpg
Foghorn Therapeutics Announces CFO Departure
January 03, 2024 16:05 ET | Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn®-logo-color.jpg
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting
December 01, 2023 07:00 ET | Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn®-logo-color.jpg
Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update
November 02, 2023 07:00 ET | Foghorn Therapeutics, Inc.
First patient dosed in FHD-286 combination study in AML; data expected in the second half of 2024Transitioned the BRM Selective inhibitor program to Loxo@LillyPresented preclinical data demonstrating...
Foghorn®-logo-color.jpg
Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs
October 24, 2023 08:00 ET | Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...